
Nordic Nanovector Investor Relations Material
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutic products for hematological cancers in Norway. The company is developing Betalutin, an antibody radionuclide conjugate, which is in Phase III clinical trial for a range of non-Hodgkin lymphoma indications. It is also developing 177Lu-lilotomab satetraxetan (HH1), a targeted alpha immunotherapy for non-Hodgkin lymphomas. The company has strategic collaboration with NRCF to develop treatment regimens for hematological cancers and other indications using Lutathera or Betalutin; and with Servier S.A.S., as well as Cytodyn Inc
Upcoming events for
Q2 20222022-07-20
Latest company events
Ticker symbol
NANOV
Country
Norway
About the company
Investor Relations Page
https://www.nordicnanovector.com/investors-and-media/investor-relations